Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SKP2 | Q13309 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | S100B | P04271 | 1/20 | 0.44 |
| ▸ | ESR1 | P03372 | 3/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.43 |
| ▸ | AR | P10275 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3775339 | 0.83 | SKP2 (0.63) | SKP2CYP3A4ALDH1A1TDP1TSHR | |
| SCHEMBL703673 | 0.82 | ALDH1A1 (0.50) | SKP2CYP3A4ALDH1A1TDP1TSHR | |
| SCHEMBL237201 | 0.81 | SKP2 (0.61) | SKP2CYP3A4ALDH1A1TDP1TSHR | |
| SCHEMBL841783 | 0.81 | SKP2 (0.73) | SKP2CYP3A4ALDH1A1TDP1TSHR | |
| SCHEMBL31079561 | 0.81 | SKP2 (0.61) | SKP2CYP3A4ALDH1A1TDP1TSHR | |
| SCHEMBL31634603 | 0.81 | SKP2 (0.73) | SKP2CYP3A4ALDH1A1TDP1TSHR | |
| SCHEMBL23093076 | 0.79 | SKP2 (0.70) | SKP2CYP3A4ALDH1A1TDP1TSHR | |
| SCHEMBL2036306 | 0.79 | SKP2 (0.59) | SKP2CYP3A4ALDH1A1TDP1TSHR | |
| Ammonia Solution, Strong SCHEMBL22344976 | 0.79 | SKP2 (0.59) | SKP2CYP3A4ALDH1A1TDP1TSHR | |
| SCHEMBL7747249 | 0.79 | SKP2 (0.64) | SKP2CYP3A4ALDH1A1TDP1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4673474-A2 | ANTI-PSMA ANTIBODIES, CONJUGATES, AND METHODS OF USE | Eisai R&D Management Co., Ltd. (JP) | 2026-01-07 | — | — | EP | disclosed |
| US-20250276074-A1 | BRM AND BRG1 TARGETING ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | PRELUDE THERAPEUTICS INCORPORATED | 2025-09-04 | — | — | US | disclosed |
| WO-2024182569-A2 | ANTI-PSMA ANTIBODIES, CONJUGATES, AND METHODS OF USE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2024-09-06 | — | — | WO | disclosed |
| EP-4237008-A2 | CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF | Elucida Oncology, Inc. (US) | 2023-09-06 | — | — | EP | disclosed |
| US-20230241243-A1 | CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF | ELUCIDA ONCOLOGY, INC. | 2023-08-03 | — | — | US | disclosed |
| US-20230241243-A1 | CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF | ELUCIDA ONCOLOGY, INC. | 2023-08-03 | — | — | US | disclosed |
| US-20230241243-A1 | CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF | ELUCIDA ONCOLOGY, INC. | 2023-08-03 | — | — | US | disclosed |
| US-20230227483-A1 | PYRIMIDINE COMPOUNDS FOR USE AS MAP4K1 INHIBITORS | GLENMARK SPECIALITY S.A. (CH) | 2023-07-20 | — | — | US | disclosed |
| US-20230227483-A1 | PYRIMIDINE COMPOUNDS FOR USE AS MAP4K1 INHIBITORS | GLENMARK SPECIALITY S.A. (CH) | 2023-07-20 | — | — | US | disclosed |
| CN-114957156-A | Compound containing benzoxazine structure, resin composition, prepreg and electric copper clad laminate, and preparation method and application thereof | 成都科宜高分子科技有限公司 | 2022-08-30 | — | — | CN | disclosed |
| US-20070043045-A1 | Novel high affinity thiophene-based and furan-based kinase ligands | SCHERING CORPORATION | 2007-02-22 | — | — | US | disclosed |
| WO-2001079195-A9 | PYRIDINE AND PYRAZINE DERIVATIVES AS THROMBIN INHIBITORS | CORVAS INT INC (US) | 2003-10-23 | — | — | WO | disclosed |
| US-6541467-B1 | And at P1 have a six-membered heterocyclic ring having two ring nitrogen ring atoms and the remainder of the ring atoms carbon atoms. | CORVAS INTERNATIONAL, INC. | 2003-04-01 | — | — | US | disclosed |
| US-6506754-B1 | Compounds as anticoagulants | CORVAS INTERNATIONAL, INC. | 2003-01-14 | — | — | US | disclosed |
| US-6506761-B1 | Compound of the invention are active as inhibitors of Thrombin and are useful in treating disease states in mammals which are characterized by abnormal thrombosis and have the following structure: | CORVAS INTERNATIONAL, INC. | 2003-01-14 | — | — | US | disclosed |
| US-6506760-B1 | Compounds of the invention are active as inhibitors of Thrombin and are useful in treating disease states in mammals which are characterized by abnormal thrombosis and have the following structure: | CORVAS INTERNATIONAL, INC. | 2003-01-14 | — | — | US | disclosed |
| WO-2001079261-A1 | TETRAHYDRO-AZEPINONE DERIVATIVES AS THROMBIN INHIBITORS | CORVAS INTERNATIONAL, INC. (US) | 2001-10-25 | — | — | WO | disclosed |
| WO-2001079193-A2 | SUBSTITUTED HYDRAZINYL HETEROAROMATIC INHIBITORS OF THROMBIN | CORVAS INTERNATIONAL, INC. (US) | 2001-10-25 | — | — | WO | disclosed |
| WO-2001079195-A2 | PYRIDINE AND PYRAZINE DERIVATIVES AS THROMBIN INHIBITORS | CORVAS INTERNATIONAL, INC. (US) | 2001-10-25 | — | — | WO | disclosed |
| WO-2001079262-A1 | PYRAZINONE AND PYRIDINONE DERIVATIVES AS THROMBIN INHIBITORS | CORVAS INTERNATIONAL, INC. (US) | 2001-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230241243-A1 | CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF | NDC1, KIFC1, SDCBP | SKP2 1344/4885CYP3A4 4060/4885ALDH1A1 1060/4885 |
| US-20070043045-A1 | Novel high affinity thiophene-based and furan-based kinase ligands | CDKL2, CDK2, CDKL1 | SKP2 31/4885CYP3A4 3394/4885ALDH1A1 4225/4885 |
| US-20250276074-A1 | BRM AND BRG1 TARGETING ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | CRBN, RBX1, SMARCE1 | SKP2 784/4885CYP3A4 4384/4885ALDH1A1 1678/4885 |
| US-20230227483-A1 | PYRIMIDINE COMPOUNDS FOR USE AS MAP4K1 INHIBITORS | MAP4K1, MAP3K4, MAP4K2 | SKP2 413/4885CYP3A4 2010/4885ALDH1A1 2196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.